Type I interferon correlates with serological and clinical manifestations of SLE

Annals of the Rheumatic Diseases

Volumn 64, Issue 12, 2005, Pages 1692-1697

  Dall'Era, M C ^a   Cardarelli, P M ^b   Preston, B T ^b   Witte, A ^b   Davis Jr , J C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Medarex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD123 ANTIGEN; CD38 ANTIGEN; DNA ANTIBODY; DOUBLE STRANDED DNA; INTERFERON; INTERFERON RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY;

ADULT; AFRICAN AMERICAN; AGED; ALPHA CHAIN; ARTICLE; CELL MATURATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; KIDNEY DISEASE; MALE; MONOCYTE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SEROLOGY; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AFRICAN AMERICANS; AGED; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; COMPLEMENT C3; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MONOCYTES; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; SEVERITY OF ILLNESS INDEX;

EID: 27944464836     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.033753     Document Type: Article

References (21)

1. Ronnblom L, Aim GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003;5:68-75.
2. Hooks JH, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8.
3. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25:401-6.
4. Friedman RM, Preble O, Black R, Harrell S. Interferon production in patients lupus erythematosus. Arthritis Rheum 1982;25:802-3.
5. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982;216:429-31.
6. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987;70:562-9.
7. von Wussow P, Jakschies D, Hartung K, Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int 1988;8:225-30.
8. Yee AM, Yip YK, Fisher HD, Buyon JP. Serum activity that confers acid lability to alpha interferon in systemic lupus erythematosus: its association with disease activity and its independence from circulating alpha interferon. Arthritis Rheum 1990;33:563-8
9. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis and Rheum 2000;43:1431-42.
10. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991;68:1536-7.
11. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity out not with antiretroviral antibodies. Lupus 2000;9:664-71.
12. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-3.
13. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interteron-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-15.
14. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-1 interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197:777-88.
15. Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in Lpr mice. J Autoimmun 2003;20:15-25.
16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheum 1982;25:1271-7.
17. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
18. Benoit P, Maguire D, Plavec I, Kocher H, Tovey M, Meyer F. A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. J Immonol 1993;150:707-16.
19. Pogue SL, Preston BT, Stalder J, Bebbington CR, Cardarelli PM. The receptor for type I IFNs is highly expressed on peripheral blood B-cells and monocytes and mediates a distinct profile of differentiation and activation of these cells. J Interferon Cytokine Res 2004;24:131-9.
20. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003;4:177-86.
21. Sbvikova M, Schmeisser H, Kontsekova E, Mateicka F, Borecky L, Kontsek P. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia. J Interferon Cytokine Res 2003;23:143-7.